Inventiva (NASDAQ:IVA) Stock Price Up 7.8% – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price shot up 7.8% during mid-day trading on Thursday. The company traded as high as $3.13 and last traded at $3.0950. 717,502 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 926,099 shares. The stock had previously closed at $2.87.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Guggenheim increased their price target on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings downgraded Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Finally, Cantor Fitzgerald started coverage on Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.86.

Inventiva Price Performance

The firm’s 50-day simple moving average is $4.11 and its two-hundred day simple moving average is $4.50.

Inventiva (NASDAQ:IVA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The business had revenue of $0.75 million for the quarter. Equities research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Platt Investment Counsel LLC acquired a new position in Inventiva during the 3rd quarter worth $45,000. Engineers Gate Manager LP increased its stake in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Inventiva in the 4th quarter valued at $603,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Inventiva during the first quarter worth $1,111,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.